Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2017 | 1 |
2019 | 1 |
2020 | 2 |
2021 | 2 |
2023 | 2 |
2024 | 1 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Five-year follow-up of 96 weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D.
Liver Int. 2024 Jan;44(1):139-147. doi: 10.1111/liv.15745. Epub 2023 Oct 3.
Liver Int. 2024.
PMID: 37787009
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Dinkelborg K, Kahlhöfer J, Dörge P, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP, Wedemeyer H, Deterding K; HIDIT-2 Study Team.
Dinkelborg K, et al. Among authors: curescu mg.
Liver Int. 2023 Aug;43(8):1663-1676. doi: 10.1111/liv.15602. Epub 2023 May 15.
Liver Int. 2023.
PMID: 37183524
Clinical Trial.
Item in Clipboard
Consensus statement on the management of patients with HCV infection in Romania.
Consensus Statement on HCV Infection in Romania Working Group.
Consensus Statement on HCV Infection in Romania Working Group.
Germs. 2017 Mar 1;7(1):32-39. doi: 10.18683/germs.2017.1106. eCollection 2017 Mar.
Germs. 2017.
PMID: 28331840
Free PMC article.
Review.
Item in Clipboard
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
Anastasiou OE, Yurdaydin C, Maasoumy B, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Liebig S, Bantel H, Bremer B, Manns MP, Cornberg M, Wedemeyer H.
Anastasiou OE, et al. Among authors: curescu mg.
J Viral Hepat. 2021 Feb;28(2):410-419. doi: 10.1111/jvh.13439. Epub 2020 Dec 12.
J Viral Hepat. 2021.
PMID: 33185325
Clinical Trial.
Item in Clipboard
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
Bremer B, Anastasiou OE, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Idilman R, Manns MP, Cornberg M, Yurdaydin C, Wedemeyer H.
Bremer B, et al. Among authors: curescu mg.
Liver Int. 2021 Feb;41(2):295-299. doi: 10.1111/liv.14740. Epub 2020 Dec 5.
Liver Int. 2021.
PMID: 33217778
Item in Clipboard
Anti-HDV IgM as a marker of disease activity in hepatitis delta.
Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group.
Wranke A, et al. Among authors: curescu mg.
PLoS One. 2014 Jul 29;9(7):e101002. doi: 10.1371/journal.pone.0101002. eCollection 2014.
PLoS One. 2014.
PMID: 25072849
Free PMC article.
Item in Clipboard
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team.
Wedemeyer H, et al. Among authors: curescu mg.
Lancet Infect Dis. 2019 Mar;19(3):275-286. doi: 10.1016/S1473-3099(18)30663-7.
Lancet Infect Dis. 2019.
PMID: 30833068
Clinical Trial.
Item in Clipboard
Cite
Cite